Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07295769

Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause

The purpose of this study is to evaluate the efficacy and safety of a wearable device in detecting previously undiagnosed atrial fibrillation through non-invasive long-term monitoring using a wearable single-lead ECG patch (MEMO Patch M, MEMO Patch2) in 100 patients with Embolic Stroke of Undetermined Source (ESUS) who require atrial fibrillation screening. Participants who meet all inclusion and exclusion criteria and provide written informed consent will wear the MEMO Patch M and undergo in-hospital telemetry monitoring using MEMO Cue for a minimum of 12 hours and up to 8 days. During hospitalization, 24-hour Holter monitoring will also be conducted. Before discharge, the investigator will review these results to determine whether implantable loop recorder (ILR) implantation is necessary. At the time of discharge, participants will wear MEMO Patch2 for up to 14 days for the first ECG monitoring period. One month after discharge, the investigator will review the results of the first monitoring and initiate the second ECG monitoring with MEMO Patch2. Three months after discharge, the results of the second ECG monitoring will be reviewed, and participation in the clinical trial will be completed.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Embolic Stroke of Undetermined Source

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Asan Medical Center

Seoul, Songpa-gu, 05505, South Korea

Location status: Recruiting

Location contact

Bum Joon Kim, MD, PhD

CONTACT

[email protected]

+82-2-3010-3981

About this study

This clinical study is designed as a prospective, single-center, investigator-initiated exploratory clinical trial.

  • Screening Participants will be assigned a screening number in the order in which informed consent is obtained. Through interviews and review of previous medical records, demographic information, medical history, surgical/procedural history, prior medications, and other required assessment items will be collected. Eligibility for study participation will be determined by reviewing the inclusion and exclusion criteria.
  • Visit 1 (In-Hospital Telemetry Monitoring) Eligible participants will be fitted with the investigational medical device, MEMO Patch M, and will undergo in-hospital telemetry monitoring using MEMO Cue for a minimum of 12 hours and up to 8 days. A 24-hour Holter monitor will also be applied after admission. Prior to discharge, participants will review the MEMO Patch M (in-hospital telemetry) results to determine whether ILR implantation is required.
  • Discharge (First ECG Monitoring) At discharge, participants who were not detected with atrial fibrillation using the Holter ECG or MEMO Patch M will receive an Implantable Loop Recorder (ILR). Participants in whom atrial fibrillation is detected will not receive ILR implantation. Regardless of ILR implantation, all participants will wear MEMO Patch2 and undergo additional ECG monitoring for up to 14 days after discharge. After the scheduled monitoring period ends, MEMO Patch2 will be returned using the Huinno courier service.
  • Visit 2 (Review of First ECG Monitoring Results - 1-Month Visit) At the 1-month outpatient visit, participants will review the results of the first ECG monitoring. They will then undergo a second monitoring period by wearing MEMO Patch2 for up to 14 days. After completing the scheduled monitoring period, MEMO Patch2 will be returned using the Huinno courier service.
  • Visit 3 (Review of Second ECG Monitoring Results - 3-Month Visit) At the 3-month outpatient visit, participants will review the results of the second ECG monitoring. After this visit, participation in the clinical study will be completed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants may take part in this clinical study only if they meet all of the following criteria:

  • Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study
  • Patients diagnosed with ESUS (Embolic Stroke of Undetermined Source)
  • Patients who require in-hospital or out-of-hospital electrocardiographic (ECG) monitoring

Exclusion criteria

Participants who meet any of the following criteria cannot be enrolled in this clinical study:

  • Individuals already diagnosed with atrial fibrillation or atrial flutter
  • Individuals with a clearly identified cause of stroke
  • Individuals known to have allergic reactions to adhesives or hydrogels
  • Individuals who, in the investigator's judgment, have cognitive vulnerability that makes it difficult to understand the study information and voluntarily decide on participation
  • Any other individuals whom the principal investigator considers to be at potential risk by participating in the study or otherwise unsuitable for participation

Treatment and study plan

MEMO Patch M and MEMO Patch2

Device

During hospitalization, participants will wear MEMO Patch M, a single-lead wearable ECG patch, for 12 hours to up to 8 days. A 24-hour Holter monitor will also be performed during hospitalization. Before discharge, investigators will review the MEMO Patch M and Holter results to assess the need for implantable loop recorder (ILR) implantation. At the time of discharge, participants will wear MEMO Patch2 for up to 14 days for the first ECG monitoring period. One month after discharge, participants will undergo the second ECG monitoring period with MEMO Patch2 for up to 14 days.

Primary outcomes

  1. Detection rate of Atrial Fibrillation (%)

    Time frame: During V1 (Day 0 to Day 8)

    The detection rate of atrial fibrillation (AF) will be evaluated based on MEMO Patch M during telemetry monitoring and 24-hour Holter monitoring. The AF detection rate by MEMO Patch M will be calculated as the number and percentage of participants in whom AF is detected at least once either through alarms or analysis results. The AF detection rate by 24-hour Holter will be calculated as the number and percentage of participants in whom AF is detected at least once during Holter analysis. The final determination of atrial fibrillation will be made according to the investigator's interpretation.

Secondary outcomes

  1. Time of Atrial Fibrillation (AF) detection

    Time frame: 30 days (+7 days) and 90 days (+7 days) post-discharge (discharge = up to Day 8)

    The timing of AF detection will be evaluated based on the results from MEMO Patch2 and ILR. This evaluation will be conducted only for patients who did not have AF detected during in-hospital telemetry monitoring and subsequently received ILR implantation.

  2. Accuracy of in-hospital monitoring alarms

    Time frame: During V1 (Day 0 to Day 8)

    For participants who triggered an AF alarm during in-hospital monitoring, the alarm accuracy will be evaluated by comparison with the final analysis results, and performance metrics such as sensitivity will be calculated.

    • True Positive (TP): AF actually occurred and the alarm was triggered.
    • False Negative (FN): AF actually occurred, but no alarm was triggered.
    • False Positive (FP): AF did not occur, but an alarm was triggered.
    • True Negative (TN): AF did not occur and no alarm was triggered.

  3. AF detection rate and burden during out-of-hospital MEMO Patch2 monitoring

    Time frame: 30 days (+7 days) and 90 days (+7 days) post-discharge (discharge = up to Day 8)

    For patients discharged without ILR implantation, additional AF detection rate and burden will be evaluated using MEMO Patch2 at Visit 2 and Visit 3.

  4. Detection rate of non-AF arrhythmias

    Time frame: During V1 (Day 0-8), 30 days (+7 days) and 90 days (+7 days) post-discharge (discharge = up to Day 8)

    The detection rate of arrhythmias other than AF will be analyzed in all participants regardless of AF detection. The following types of non-AF arrhythmias will be included:

    • Atrial Premature Contractions (APC)
    • Ventricular Premature Contractions (VPC)
    • Supraventricular Tachycardia (SVT): Defined as three or more consecutive APCs.
    • Ventricular Tachycardia (VT): Defined as three or more consecutive VPCs.
    • Atrioventricular Block (AV Block): Includes second-degree and third-degree AV block.
    • Pause: Defined as an R-R interval of more than 2 seconds.
    • Other: Arrhythmias not included in the above categories.

  5. Analysis of arrhythmia types including AF

    Time frame: During V1 (Day 0-8), 30 days (+7 days) and 90 days (+7 days) post-discharge (discharge = up to Day 8)

    In participants in whom arrhythmias, including atrial fibrillation, were detected, the type of each arrhythmia will be evaluated. (including its duration and burden)

  6. Risk factor analysis for AF occurrence

    Time frame: Screening (Day-28 to Day 0), 30 days (+7 days) and 90 days (+7 days) post-discharge (discharge = up to Day 8)

    In participants with detected AF, ethe type of each arrhythmia(duration, and burden), including AF, will be evaluated. 6) To analyze factors associated with AF occurrence in patients with Embolic Stroke of Undetermined Source (ESUS), the following parameters will be assessed:

    • Frequency of Atrial Premature Contractions (APC)
    • Age
    • CHA₂DS₂-VA Score
    • Left Atrial Size (LA diameter, LA volume index)
    • Lesion Pattern
    • Laboratory Test Results
    • Risk factors will be analyzed post hoc only for participants with available data.

  7. Rate and timing of treatment strategy changes (Including medication and procedures) after AF diagnosis

    Time frame: During V1 (Day 0-8), 30 days (+7 days) and 90 days (+7 days) post-discharge (discharge = up to Day 8)

    In participants who were receiving standard treatment for ESUS, the proportion and timing of treatment changes will be analyzed if AF diagnosis via MEMO Patch monitoring led to:

    • Initiation or switching of anticoagulant therapy
    • Initiation or switching of antiarrhythmic drugs
    • Catheter ablation or other procedure-related changes

  8. Comparison of AF detection rates and timing between two monitoring strategies (MEMO Patch M + MEMO Patch2 vs. Holter + ILR)

    Time frame: During V1 (Day 0-8), 30 days (+7 days) and 90 days (+7 days) post-discharge (discharge = up to Day 8)

    The AF detection rate and timing will be compared between MEMO Patch M and MEMO Patch2 versus Holter and ILR during in-hospital and out-of-hospital monitoring.

Study contacts

Contact information is provided by the study sponsor or research team.

Bum Joon Kim

CONTACT

[email protected]

+82 02-3010-3981

Sponsors and collaborators

Lead sponsor

Asan Medical Center

Other

Registry information

Official study title

Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause: A Single-Center, Prospective, Exploratory Trial to Validate the Efficacy and Safety of Noninvasive Long-Term Electrocardiographic Monitoring

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Dec 22, 2025
Registry last updated
Feb 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.